NasdaqCM:VRDNBiotechs
Viridian Therapeutics (VRDN) Wins FDA Approval For Lumvoa, Is The Upside Already Priced In?
Viridian Therapeutics (VRDN) is in focus after the U.S. Food and Drug Administration approved Lumvoa for thyroid eye disease, covering both active and chronic forms. The stock moved 6% higher after hours.
See our latest analysis for Viridian Therapeutics.
Viridian Therapeutics’ latest FDA approval comes after a mixed stretch for holders, with the share price down 40.11% year to date but a 1 year total shareholder return of 26.99%. This suggests sentiment has shifted recently as new catalysts...